Actinium-225 (Ac-225) Market
完整報告名稱與涵蓋範圍
Actinium-225 (Ac-225) Market Size, Share & Trends Analysis Report, By Production Route (Thorium-229 Generator Decay, Accelerator-Based Production (Ra-226 and Th-232 Targets), Reactor-Based and Photonuclear Production), By Application (PSMA-Targeted Prostate Cancer Therapy, Neuroendocrine Tumor Therapy, Hematologic Malignancies, Other Solid Tumor Radioligand Programs), By End User (Radiopharmaceutical Developers, Contract Manufacturers and Radiopharmacies, Academic and Research Institutes), By Region, and Segment Forecasts, 2026-2035
報告摘要
The actinium-225 market covers the production, purification and commercial supply of the alpha-emitting radionuclide Ac-225 used to label targeted alpha therapies, together with the associated radiochemical grades, shipping and generator formats. Revenue is measured at the isotope-supply layer, from producers to radiopharmaceutical developers, contract manufacturers and radiopharmacies, and excludes the value of finished Ac-225-labelled drugs, which is captured in therapeutic market studies.
Demand is being pulled forward by a clinical pipeline of PSMA-, SSTR- and FAP-targeted alpha therapies that require gigabecquerel-scale quantities the legacy thorium-229 stockpiles at national laboratories cannot supply. The response has been a wave of new routes: accelerator production from radium-226 and thorium-232 targets, photonuclear and cyclotron approaches, and expanded generator programs, each with distinct purity profiles that influence which programs can use them. Long-term offtake agreements between drug developers and producers, regulatory acceptance of accelerator-derived material, and investment in dedicated alpha-capable manufacturing suites are shaping the commercial model, while radium sourcing, transport rules and waste handling remain practical constraints.
North America and Europe host most producers and the majority of sponsor demand, with new capacity coming online in Canada, the United States, Germany and Belgium; Japanese and Chinese isotope programs are emerging. Competition combines specialist isotope producers, nuclear technology groups diversifying into medical isotopes and pharmaceutical companies securing captive supply through partnerships and acquisitions.
The InsightAce study supplies US$ forecasts for all production route, application and end user and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Actinium-225 (Ac-225) Market Snapshot
Chapter 4. Global Actinium-225 (Ac-225) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Production Route Estimates & Trend Analysis
5.1. Production Route & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Production Route:
5.2.1. Thorium-229 Generator Decay
5.2.2. Accelerator-Based Production (Ra-226 and Th-232 Targets)
5.2.3. Reactor-Based and Photonuclear Production
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. Application & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Application:
6.2.1. PSMA-Targeted Prostate Cancer Therapy
6.2.2. Neuroendocrine Tumor Therapy
6.2.3. Hematologic Malignancies
6.2.4. Other Solid Tumor Radioligand Programs
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Radiopharmaceutical Developers
7.2.2. Contract Manufacturers and Radiopharmacies
7.2.3. Academic and Research Institutes
Chapter 8. Actinium-225 (Ac-225) Market: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. United States
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. United Kingdom
8.2.3. France
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia Pacific
8.3.1. China
8.3.2. Japan
8.3.3. India
8.3.4. South Korea
8.3.5. Australia
8.3.6. Southeast Asia
8.3.7. Rest of Asia Pacific
8.4. Latin America
8.4.1. Brazil
8.4.2. Mexico
8.4.3. Rest of Latin America
8.5. Middle East & Africa
8.5.1. GCC Countries
8.5.2. South Africa
8.5.3. Rest of Middle East & Africa
Chapter 9. Competitive Landscape
9.1. Company Market Positioning Analysis
9.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 10. Company Profiles
10.1. TerraPower Isotopes
10.2. Eckert & Ziegler SE
10.3. ITM Isotope Technologies Munich SE
10.4. NorthStar Medical Radioisotopes, LLC
10.5. BWXT Medical Ltd.
10.6. Nusano, Inc.
10.7. Niowave, Inc.
10.8. PanTera NV (IBA/SCK CEN)
10.9. Curium
10.10. Bayer AG
10.11. Novartis AG (Advanced Accelerator Applications)
10.12. AstraZeneca plc (Fusion Pharmaceuticals)
10.13. Bristol Myers Squibb (RayzeBio)
10.14. Actinium Pharmaceuticals, Inc.
圖表清單 List of Tables & Figures
Table 1. Global Actinium-225 (Ac-225) Revenue Forecast by Production Route, 2026-2035 (US$ Mn)
Figure 1. Global Actinium-225 (Ac-225) Market Snapshot, 2026 & 2035
Table 2. Global Actinium-225 (Ac-225) Revenue Forecast by Application, 2026-2035 (US$ Mn)
Figure 2. Global Actinium-225 (Ac-225) Market Share by Application, 2026 & 2035
Table 3. Global Actinium-225 (Ac-225) Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Ac-225 Production Route Comparison by Purity Profile and Scalable Capacity
Table 4. North America Actinium-225 (Ac-225) Revenue by Country, 2026-2035 (US$ Mn)
Figure 4. Global Ac-225 Supply Versus Clinical and Commercial Demand Outlook, 2026-2035
Table 5. Europe Actinium-225 (Ac-225) Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Actinium-225 (Ac-225) Growth Opportunity Analysis
Table 6. Asia Pacific Actinium-225 (Ac-225) Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Offtake Agreements and Supply Partnerships Between Producers and Drug Developers
Table 7. Latin America and Middle East & Africa Actinium-225 (Ac-225) Revenue Forecast, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Actinium-225 (Ac-225) Market Participants
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們